Radiographic indicators and baseline disease characteristics
| RRR-achieved (N=33) | RRR-failed (N=16) | p (probability >χ2) | |
|---|---|---|---|
| Baseline | |||
| Disease duration (years) | 4.7 (0.5–14.0) | 8.6 (0.5–25.0) | 0.0280 |
| DAS28 (ESR) score | 5.5 (1.9–7.6) | 5.7 (4.2–6.8) | 0.6976 |
| HAQ-DI | 1.0 (0.0–2.3) | 1.1 (0.0–1.8) | 0.6271 |
| mTSS | 46.9 (1.0–216.5) | 97.2 (6.0–314.0) | 0.0207 |
| Bone erosion score | 23.7 (0.0–127.5) | 55.5 (1.5–192.5) | 0.0119 |
| Joint space narrowing score | 23.2 (1.0–89.0) | 41.6 (4.5–121.5) | 0.0621 |
| Yearly progression of mTSS | 13.1 (0.8–51.3) | 15.0 (1.0–47.8) | 0.5794 |
| RRR-entry | |||
| Yearly progression of mTSS | 1.0 (−2.9 to 10.5) | 0.7 (−2.0 to 6.7) | 0.5788 |
| Primary end point | |||
| Yearly progression of mTSS | 0.3 (−3.6 to 8.5) | 1.6 (–3.6 to 7.0) | 0.1087 |
| Median of yearly progression of mTSS | 0.0 | 1.5 | – |
| Yearly progression of mTSS <0.5 (%) | 67 | 44 | 0.2161 |
Data are number of patients (%) for categorical data and the means for continuous data. Statistical difference was assessed by non-parametric Wilcoxon t test and p (probability >χ2) values were shown. Values in italic indicate a significant difference (p<0.05).
DAS28, Disease Activity Score based on assessments of 28 tender and 28 swollen joints; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; mTSS, modified total Sharp score; RRR, remission induction by Remicade in rheumatoid arthritis.